EP1.01-102 Efficacy and Toxicity of Erlotinib and Gefitinib in Moroccan Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation

Lung cancer, the second most common cancer in Morocco, is a public health problem. It is also the leading cause of cancer death in the world because its prognosis is poor and the diagnosis is often made at a metastatic stage. The advent of tyrosine kinase inhibitors has improved survival in patients with epidermal growth factor receptor mutation (EGFR) There are few studies in Morocco, the aim of this study was to evaluate the efficacy and safety of anti-EGFR in patients with non-small cell lung cancer with EGFR mutated in Morocco. We had collected twenty-three patients followed for metastatic non-small cell lung cancer with EGFR mutation and management in the onco-radiotherapy department of the IBN ROCHD University Hospital of Casablanca (MOROCCO) Of the twenty-three patients collected, the sex ratio was 7 men to 16 women, the average age was 59 years, only one case had a history of smoking, all cases had adenocarcinoma, the mutation on exon 19 was found in 87%. The median progression-free survival was 4 months and the median overall survival was 12 months, For tolerance; diarrhea and folliculitis were found in all patients with 50% grade II. The EGFR mutation appears to be more frequent in women and non-smokers, and anti-EGFR treatment improves survival with a particular tolerance profile that should be known.